Kathleen Scott PhD, is a Clinical Program Leader at Cancer Trials Ireland (formerly ICORG) and is responsible for the oversight of a number of cancer and haematology trials programs.
She has gained more than 20 years cancer clinical research experience in academic, clinical, and pharmaceutical settings throughout the UK, Australia, and Ireland. Since arriving in Ireland 5 years ago, she was awarded a Cochrane Fellowship based at Trinity College Dublin by the Health Research Board. In her role at Cancer Trial Ireland, she co-leads a team of approximately 30 clinical research staff working across a diverse range of clinical trials and has program responsibility for haematology trials including multiple myeloma.
She has worked proactively with lead haematologists in Ireland, international collaborators and pharmaceutical partners to design and develop new trials and bring new myeloma treatments to patients in Ireland. Kathleen published a Cochrane Review in 2016 titled ‘Bortezomib for the treatment of multiple myeloma’.
